Anti-CDKN1B/p27KIP1 Rabbit Polyclonal Antibody for WB, IHC-P, ELISA - P46527

Core Product Specifications and Parameters

Biological Background: CDKN1B/p27KIP1 Function and Localization

• CDKN1B/p27KIP1 is a key cyclin-dependent kinase inhibitor that regulates cell cycle progression by inhibiting CDK2/cyclin A complexes, though it shows little activity against CDK2 bound to SPDYA. Related references: PMID:28666995
• It enforces G1 arrest by potently inhibiting cyclin E-CDK2 and cyclin A-CDK2 complexes.
• p27 also interacts with cyclin D-CDK4 complexes, contributing to their assembly, stability, and modulation, and can act as either an inhibitor or activator depending on phosphorylation state and stoichiometry.
• The protein is predominantly nuclear but also localized in the cytoplasm and endosomes, reflecting dynamic roles in multiple compartments.
• Tissue expression is ubiquitous, with highest levels in skeletal muscle and lower levels in liver and kidney; it is detected in kidney at the protein level.
• Keywords include cell cycle regulation, phosphoprotein, protein kinase inhibitor, tumor suppression, and ubiquitin-like conjugation, highlighting its post-translational control.

Experimental Guidance and Technical Tips

• The immunogen corresponds to full-length human CDKN1B/p27 (aa 1-198); therefore, the antibody is expected to recognize the native and denatured protein.
• For western blotting, a band around 22 kDa is anticipated; using lysates from human, mouse, or rat tissues (especially skeletal muscle or kidney) may help verify specificity.
• In IHC-P, nuclear and/or cytoplasmic staining may be observed; optimization of antigen retrieval and primary antibody concentration is recommended.
• Since the antibody has not been tested in other applications (e.g., IF, FC), pilot studies should be performed to assess suitability.

CamelBio: Your One-Stop Sourcing Bridge

CamelBio streamlines sourcing of high-quality IVD raw materials, including validated antibody pairs and optimized polyclonal antibodies like this anti-CDKN1B/p27KIP1 antibody. We support cell cycle and oncology research with bulk ancillary reagents and rare-target sourcing, ensuring seamless procurement from concept to clinic.